SMS. N. Mekhtiyev

S. N. Mekhtiyev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. N. Mekhtiyev has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic-associated fatty liver disease and hypertriglyceridemia: cardiovascular risks and current therapeutic approaches

    by Yu. Sh. Khalimov, M. V. Yezhov, K. L. Raikhelson, A. O. Bueverov, F. Kh. Dzgoeva, S. N. Mekhtiev, A. G. Obrezan, S. V. Okovity, E. A. Polyakova, A. E. Filippov, et al.

    Metabolic-associated fatty liver disease (MAFLD) is a systemic disorder associ-ated with metabolic dysfunction and a high risk of life-threatening conditions, primarily cardiovascular disease. MAFLD is often accompanied by hypertriglyceridemia (HTG), as both conditions share a common pathogenetic mechanism — insulin resistance. Both HTG and MAFLD contribute to an increased risk of cardiovascular disease, necessitating personalized HTG treatment algorithms in patients with MAFLD. This paper presents an interdisciplinary expert perspective, summarizing current data on the epidemiology, pathogenesis, clinical features, and management strategies for patients with MAFLD and concomitant HTG. Non-drug approach and pharmacotherapy are discussed, including lifestyle modification, lipid-lowering therapy, and the use of hepatotropic agents. Particular attention is paid to the safety of lipid-lowering therapy. The presented data are based on the results of expert discussion and rationales an early, interdisciplinary, and personalized approach aimed at treating metabolic disorders, reducing cardiovascular risk, and managing liver disease.

  • Open Access

    Fixed-Dose Combinations of Glycyrrhizic Acid + Phospholipids and Glycyrrhizic Acid + Ursodeoxycholic Acid in the Treatment of Non-Alcoholic Fatty Liver Disease (Literature Review and Expert Council Resolution)

    by S. V. Okovityi, K. L. Raikhelson, A. O. Bueverov, E. V. Vinnitskaya, V. R. Grechishnikova, M. S. Zharkova, K. V. Ivashkin, M. V. Maevskaya, S. N. Mekhtiev, I. G. Nikitin, et al.

    Aim: to evaluate, based on an analysis of preclinical and clinical data, the efficacy and safety of fixed combinations of glycyrrhizic acid with phospholipids or ursodeoxycholic acid for the treatment of non-alcoholic fatty liver disease. Key points. Glycyrrhizic acid exerts antisteatotic, anti-inflammatory, and antifibrotic effects through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), the inhibition of sterol regulatory element-binding protein 1c (SREBP-1c), nuclear factor κB (NF-κB), and the modulation of the farnesoid X receptor (FXR)/sirtuin-1 (SIRT1) pathway. The “glycyrrhizic acid + phospholipids” fixed-dose combination (IV for 14 days followed by PO for 10 weeks) is recommended to reduce steatosis and inflammation and to prevent fibrosis (strength of recommendation: B; level of evidence: 2). In clinical studies, a 2–3-month therapy with the drug led to the normalization of aminotransferase activity in the majority of patients, while a 12-month study demonstrated regression of advanced stages of liver fibrosis (F2–F4), up to the complete disappearance of signs of cirrhosis (F4) in all patients. The “glycyrrhizic acid + ursodeoxycholic acid” fixed combination (12 weeks; 15 mg/kg/day of ursodeoxycholic acid) is recommended for patients with non-alcoholic fatty liver disease and elevated aminotransferase levels to reduce inflammation (strength of recommendation: B; level of evidence: 2). Randomized clinical trials have shown more than a twofold reduction in aminotransferase activity, as well as improvements in quality of life. An analysis of more than 1.3 million prescriptions confirms a favorable safety profile for both combinations (overall incidence of adverse events: 0.01–1.4 %, predominantly mild gastrointestinal disturbances). Conclusion. Fixed-dose combinations of “glycyrrhizic acid + phospholipids” and “glycyrrhizic acid + ursodeoxycholic acid” are effective and safe pharmacotherapeutic options for the treatment of non-alcoholic fatty liver disease, exhibiting antisteatotic, anti-inflammatory, and antifibrotic effect as supported by data from randomized clinical trials and post-marketing surveillance in the Russian Federation.

  • Open Access

    Classification, Diagnosis, and Management of Patients with Biliary Sludge and Early-Stage Cholelithiasis (Literature Review and Expert Council Resolution)

    by S. R. Abdulkhakov, D. S. Bordin, O. S. Vasnev, N. N. Vetsheva, O. Yu. Zolnikova, Yu. A. Kucheryavyy, S. N. Mekhtiev, A. V. Okhlobystin, E. V. Parfenchikova, K. L. Raikhelson, et al.

    Background. On May 20, 2025, a Council of Experts was held in Moscow. The aim of the meeting was to discuss current understanding of the pathogenesis and clinical significance of biliary sludge. Key points. The following definition of biliary sludge has been established: echogenic fluid within the gallbladder cavity without a clear acoustic shadow, which shifts with changes in body position without fragmentation into fine particles. The absence of an acoustic shadow distinguishes sludge from gallstones. The International Consensus of Experts in Pancreatobiliary Diseases (2023) proposed distinguishing between biliary sludge, microlithiasis (echogenic stones ≤ 5 mm with acoustic shadowing), and larger gallstones in the gallbladder and/or ducts. When managing a patient with biliary sludge, it is important to identify the underlying disease or condition predisposing to the development of sludge. The most important factors are genetic and demographic ones, dietary habits, conditions associated with rapid weight loss, and medications that affect bile composition or gallbladder function. Biliary sludge can be asymptomatic, with dyspeptic symptoms, or lead to complications typical of gallstones. Some data suggest that sludge is associated with idiopathic pancreatitis. The primary diagnostic method for sludge is transabdominal ultrasound. If clinical manifestations characteristic of cholelithiasis complications develop, the common bile duct becomes dilated, or stones are detected in the common bile duct, additional diagnostic testing using magnetic resonance cholangiopancreatography and/or endoscopic ultrasound is recommended. Clinical observations also suggest the potential for sludge to transform into gallstones. However, the view that biliary sludge is the first stage of gallstone disease was not shared by all Council members due to the high incidence of reversible sludge. At this stage, it is proposed to consider biliary sludge more as a risk factor or a specific form of gallstone disease. The only medication shown to dissolve biliary sludge is ursodeoxycholic acid. Conclusion. The Expert Council adopted a resolution, the provisions of which emphasize the need for accurate diagnosis, individual assessment of risk factors for the development of biliary sludge, the feasibility of developing a scoring system for assessing biliary sludge, determining the location of ursodeoxycholic acid therapy for sludge, and the need to supplement the Clinical Guidelines of the Russian Ministry of Health for the diagnosis and treatment of cholelithiasis with sections devoted to the diagnosis and treatment of biliary sludge.


  • Open Access

    Liver fibrosis as a major prognostic factor in chronic liver diseases and a key target for pharmacotherapy

    by S. N. Mekhtiev, O. A. Mekhtieva, O. M. Berko, A. S. Lovitskiy

    Introduction . According to the available data from literature, non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in Russia and worldwide. The stage of liver fibrosis (LF) determines the prognosis for patients. Liver fibrogenesis is a potentially reversible process and requires timely initiation of therapy. Aim . To provide current information on the prevalence of LF, the mechanisms of its development and therapeutic options in patients with NAFLD, as well as practical evaluation of the antifibrotic effects of essential phospholipid (EP) combined with glycyrrhizic acid (GA). Materials and methods . A total of 83 people (mean age 61.4 ± 3.27 years, a male-to-female ratio 65:18, body mass index no more than 40 kg/m 2 ) were included in the study. The stage of liver fibrotic changes was evaluated using dynamic ultrasound transient shear-wave fibroelastography before therapy initiation, at 6 and 12 months of therapy. The patients were divided into 2 groups: group 1 (n = 39) received a fixed-dose combination of EP/GA, group 2 (n = 44) received EP. Liver steatosis was the predominant condition in 59 individuals, while non-alcoholic steatohepatitis was present in 24 patients. Results . The evaluation of six-month fixed-dose EP/GA therapy showed significant regression of LF indicators in group 1, which was mainly observed in fibrotic changes F2. After 12 months of fixed-dose EP/GA therapy, the number of patients with LF F2 and LF F3 also significantly regressed from 49% to 31% and from 38% to 23%, respectively. The EP monotherapy only demonstrated its efficacy in patients with fibrotic changes F1. Conclusion . The fibrogenesis processes may be slowed down, and in some cases regressed, during the long-term use of the combination drug EP/GA, which demonstrated its efficacy and safety in clinical trials and in real-life clinical practice.


  • Open Access

    A new look at the classification of gallstone disease

    by S. N. Mekhtiev, O. A. Mekhtieva

    Given the new diagnostic possibilities using endoultrasonography, the authors propose to supplement the definition of “gall-stone disease” (GSD), i.e. to consider it as a chronic hepatobiliary disease, in which not only stones, but also microcholelithiasis (microcholecysto- and/or microcholedocholithiasis), and biliary sludge are forming in the bile ducts. The article discusses a new draft classification of GSD, diagnostic criteria, and features of the clinical course of different stages of GSD. The therapy with a fixed-dose combination of GA and UDCA has become one of the promising approaches to the treatment of GSD, which reduces the risk of progression and complications of the disease at all its stages, as well as after cholecystectomy. Based on the analysis of available research papers and our own clinical experience, this topical article discusses a new draft classification of GSD based on new diagnostic methods, which is proposed for consideration by surgical and non-surgical specialists. The work presents diagnostic criteria, features of the clinical course of different stages of GSD, and points to the fact that complications such as acute pancreatitis and cholangitis may develop even with stage I GSD. Attention was also being given to the question of incorporating a section on different post-cholecystectomy conditions into the classification of GSD. The article presents the principles of pharmacotherapy for GSD based on the pathogenetic mechanisms by which it develops. The ursodeoxycholic acid is a multi-purpose combination drug, whose effect is potentiated by glycyrrhizic acid added to it. Improvement of the classification of GSD, including its stage I and the post-cholecystectomy condition, is needed to study the features of the clinical picture, prognosis for stone formation and the risks for complications, as well as optimization of disease management.

  • Opportunities of combination therapy for chronic liver diseases: results of the multicenter PROMETHEUS study

    by Ch.S. Pavlov, T.A. Turankova, D.A. Teplyuk, A.V. Mudrova, Yu.P. Uspenskiy, S.N. Mekhtiev, I.G. Nikitin, A.O. Bueverov, M.F. Osipenko, A.A. Poromov

    The global prevalence of chronic liver diseases (CLD) is steadily increasing, with the most common etiologies being metabolic disorders and alcohol misuse. Despite the effectiveness of non-pharmacological interventions, their impact is often insufficient. Objective. To conduct a clinical and epidemiological analysis of common forms of CLD —nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and drug-induced liver injury (DILI) — in outpatient practice, and to assess the use of hepatotropic agents, including combination therapy with glycyrrhizic acid and phospholipids (GA+PL). Material and methods. The multicenter PROMETHEUS study comprised two stages: a retrospective analysis of 9.149 medical records and a prospective non-interventional observation of 574 patients treated with GA+PL (Phosphogliv). Changes in biochemical liver function parameters, treatment tolerability, and adverse event rates were evaluated. Results. NAFLD accounted for 72.8% of cases, ALD for 20.1%, and DILI for 7.1%. Comorbidities were present in 90% of patients, and non-pharmacological interventions were prescribed in 95.1%. Monotherapy with hepatotropic agents was associated with reductions in ALT and AST levels (ΔALT 17.28±17.46 U/L; ΔAST 15.04±15.45 U/L). Combination therapy with GA+PL achieved normalization of ALT, AST, and ALP in patients with initially elevated enzyme levels within comparable time frames (p<0.05). At the end of GA+PL therapy, AST normalized in 69% of patients and ALT in 45%. A stepwise regimen (parenteral followed by oral administration) resulted in ALT normalization in 53.5% of patients after a 3-week course. Subjective improvement was reported by over 99% of patients, while the incidence of adverse events was 0.03%. Conclusions. In outpatient practice, NAFLD predominates among CLD cases. Monotherapy with hepatotropic agents reduces liver enzyme activity, while combination therapy with GA+PL yields greater improvements in clinical and biochemical parameters. A stepwise regimen shortens treatment duration without compromising efficacy.


  • Open Access

    Stage I cholelithiasis. Approaches to diagnosis and treatment. Results of the Machaon study

    by S N Mekhtiev, O A Mekhtieva, I G Nikitin, S V Okovityy, C S Pavlov, A O Bueverov, M F Osipenko, S V Turkina, L G Vologzhanina, E V Beloborodova, et al.

    Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA.

  • Open Access

    Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease

    by V. T. Ivashkin, O. M. Drapkina, M. V. Maevskaya, K. L. Raikhelson, S. V. Okovityi, M. S. Zharkova, V. R. Grechishnikova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, et al.

    Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.


  • Open Access

    Rationale for choosing antihypertensive therapy in a patient with NAFLD and arterial hypertension

    by S. N. Mekhtiyev, O. A. Mekhtiyeva, O. M. Berko

    The concept of metabolic syndrome (MS) has existed since the 1980s and in its classical version includes obesity, lipid and carbohydrate metabolism disorders, and arterial hypertension (AH). Later (since 2009), non-alcoholic fatty liver disease (NAFLD) was considered as the fifth component of MS, which is currently proposed to be renamed steatotic liver disease by the International Working Group “Multi-Society and Multi-Stakeholder Consensus Revision of the NAFLD Nomenclature”. NAFLD and AH are pathogenetically interconnected through insulin resistance, systemic inflammatory response and oxidative stress, progressive endothelial dysfunction, impaired vasoconstriction and vasodilation mechanisms that develop against the background of liver fibrogenesis, which is described in detail in this article. Patients with hypertension and NAFLD often have unstable hypertension with episodes of hypotension, and insufficient effectiveness of antihypertensive therapy. NAFLD itself is associated not only with an increased risk of cardiovascular events, but also with other cardiac complications, regardless of traditional cardiovascular risk factors. At the same time, hypertension increases the risk of liver cirrhosis and, in addition, hypertension is independently associated with the development of severe liver diseases. In other words, the combination of NAFLD and hypertension in a patient worsens the course of both pathologies and the patient’s prognosis, especially with progressive fibrosis in the liver. Pathogenetically substantiated drugs of choice in the treatment of hypertension in a patient with NAFLD are drugs that affect the renin-angiotensin system, which will also be discussed in this article.

  • Open Access

    The role of cholelithiasis and cholecystectomy in the prognosis of non-alcoholic fatty liver disease: Recommendations for patient management

    by S. N. Mehtiev, O. A. Mehtieva

    There is a close connection between cholelithiasis (GSD) and non-alcoholic fatty liver disease (NAFLD). It is based on common risk factors, insulin resistance, disorders of carbohydrate and lipid metabolism, hepato-enteric circulation (HEC) of bile acids and the state of intestinal microflora. Chole-cystectomy (CE) is currently considered as an independent risk factor for the development and progres-sion of NAFLD and metabolic disorders in patients with cholelithiasis.That is why a patient suffering from cholelithiasis and NAFLD needs an individual approach before cholecystectomy. Patients with cholelithiasis and NAFLD are recommended to undergo a dynamic monitoring after cholecystectomy. The monitoring includes a control of general condition, biochemical parameters of the liver, lipid and carbohydrate metabolism, liver fibroelastography parameters. The treatment for this category of patients is aimed at eliminating risk factors, strict adherence to diet, phys-ical activity regimen, in order to correct obesity, dyslipidemia, hyperglycemia, the use of drugs that im-prove the condition of the hepatocytes, lipid and carbohydrate metabolism, the metabolic function of hepatocytes and inhibiting the processes of fibrogenesis in liver. At the same time, the common medi-cines of this category of patients are ursodeoxycholic acid, glycyrrhizic acid, phospholipids, antioxi-dants, and drugs to cure bacterial overgrowth syndrome in the intestines.